Patients with concomitant CKD and heart failure exhibit marked morbidity and mortality, and future research into SZC use in this population could provide a workaround for provider ACE inhibitor prescription reluctance while avoiding potentially severe GI side effects of other accepted medications used to correct hyperkalemia in heart failure patients [28,29]. This evidence concerns the gene ACE and Hyperkalemia.